Influenza A virus H5N1 subtype Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Influenza A virus H5N1 subtype

September 2018 | 65 pages | ID: I14BEA9A872EN
VPAResearch

Abstracts

Influenza A virus H5N1 subtype Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Influenza A virus H5N1 subtype Infection pipeline products.

DISEASE OVERVIEW

Influenza A virus H5N1 subtype infection is spread through Clostridium tetani bacteria, which is present in the form of spores in the environment and develops as bacteria upon entering into human body. Painful muscle contractions are the primary symptom and the disease is also referred to as ‘lockjaw’ as jaw muscles are tightened in tetanus infected patient.

Different forms of tetanus include - general, local and cephalic tetanus. Sudden spasms of the vocal cords, fractures, infections, aspiration pneumonia are the major complications of the disease.

Despite low costs of treatment, tetanus is rapidly progressing infectious disease, causing mortality. Fourteen companies are currently developing vaccines and treatment options against tetanus infections. The companies in global tetanus pipeline include - Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma - Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi, Serum Institute of India Ltd and Wockhardt Ltd.

REPORT DESCRIPTION

The Influenza A virus H5N1 subtype Infection pipeline guide presents complete overview of drugs currently being developed for Influenza A virus H5N1 subtype Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Influenza A virus H5N1 subtype Infection pipeline candidate.

Research and Development progress along with latest news related to each of the Influenza A virus H5N1 subtype Infection pipeline candidates is included.

Major companies participating in therapeutic development of Influenza A virus H5N1 subtype Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Influenza A virus H5N1 subtype Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Influenza A virus H5N1 subtype Infection clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Influenza A virus H5N1 subtype Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF INFLUENZA A VIRUS H5N1 SUBTYPE INFECTION PIPELINE REPORT INCLUDES

• Panorama of Influenza A virus H5N1 subtype Infection pipeline markets including statistics on therapeutic drugs and companies involved
• Influenza A virus H5N1 subtype Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
• Influenza A virus H5N1 subtype Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
• Overview of companies participating in Influenza A virus H5N1 subtype Infection pipeline with short introduction to their businesses and pipeline projects
• For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
• Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Influenza A virus H5N1 subtype Infection pipeline therapeutics

REASONS TO BUY

• Get clear understanding of the entire Influenza A virus H5N1 subtype Infection pipeline, with details on active projects
• Get in detail information of each product with updated information on each project along with key milestones
• Know the list of companies participating in global Influenza A virus H5N1 subtype Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

Contents

I. KEY FINDINGS

1. Companies Investing in Influenza A virus H5N1 subtype Infection Pipeline include
  Number of Companies with Influenza A virus H5N1 subtype Infection projects in pre-clinical Development
  Number of Companies with Influenza A virus H5N1 subtype Infection projects in Clinical Development
  Influenza A virus H5N1 subtype Infection Pipeline Companies based in Americas
  Influenza A virus H5N1 subtype Infection Pipeline Companies based in Europe
  Influenza A virus H5N1 subtype Infection Pipeline Companies based in Asia Pacific
  Influenza A virus H5N1 subtype Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include
  Influenza A virus H5N1 subtype Infection Pipeline Agents in Pre- clinical/Discovery stage of Development
  Influenza A virus H5N1 subtype Infection Pipeline Agents in Clinical Development stage
  Influenza A virus H5N1 subtype Infection Pipeline Therapeutic Compounds received special status
  Mechanism of Action of most pipeline Drugs
  Small molecules among the Influenza A virus H5N1 subtype Infection Pipeline agents

II. INSIGHTS INTO INFLUENZA A VIRUS H5N1 SUBTYPE INFECTION PIPELINE

1. Disease Overview
  Introduction to Influenza A virus H5N1 subtype Infection
  Symptoms and Causes of Influenza A virus H5N1 subtype Infection
  Treatment or Prevention Options for Influenza A virus H5N1 subtype Infection
  Other Details
2. Phase wise Pipeline Compounds
  Influenza A virus H5N1 subtype Infection Pipeline Pre- Clinical/Discovery stage Drugs
  Influenza A virus H5N1 subtype Infection Pipeline Phase 1 stage Drugs
  Influenza A virus H5N1 subtype Infection Pipeline Phase 2 stage Drugs
  Influenza A virus H5N1 subtype Infection Pipeline Phase 3 stage Drugs
  Influenza A virus H5N1 subtype Infection Pipeline Pre-Registration stage Drugs
3. Company wise Influenza A virus H5N1 subtype Infection Pipeline Compounds
4. Influenza A virus H5N1 subtype Infection Pipeline by Mechanism of Action

III. INFLUENZA A VIRUS H5N1 SUBTYPE INFECTION PIPELINE COMPOUND DETAILS

Neuraminidase inhibitor for H5N1
avian influenza vaccine
Pandemic influenza H5 and H1B vaccine
NasoVAX
Influenza A virus H5N1 vaccine
APP-0205
APP-309
MD 2009
BVX-M001
Nasal influenza vaccines
peptide treatment for H5N1
Small Molecules for Influenza A Virus H5N1
CHO-S05
CC-42344
CV7302
DP-C005
PN-SIA
PN-SIA
sirtuin-targeted drugs for influenza virus
GammaFlu
siRNA antivirals
GREFLU/VIE
Ampligen
KPT-335
KIN 1148
Influ-nRNA
H5N1 virus-like particle vaccine
influenza (H5, H7, H9 and H10 )VLP vaccine
AT-301
FLU-CIDE
GelVac vaccine
influenza H5N1 vaccine
influenza virus haemagglutinin glycoprotein inhibitors
Baloxavir Marboxil
MV-4
Pandemic H5N1 vaccine
split-virion H5N1 vaccine
VX-787
HB36.6
Drug Details
  1. Snapshot
    Name of the Therapeutic Agent
     Originator
    Developing Company
    Co-Developer/License Partner
    Orphan Drug/Fast Track/Designation
    Development Phase
  2. Drug Overview
  3. Mechanism of Action
  4. Current Status
  5. Clinical Trial Details

IV. INFLUENZA A VIRUS H5N1 SUBTYPE INFECTION PIPELINE COMPANY BRIEFS

Abzyme Therapeutics LLC
Akshaya Bio Inc
AlphaVax
Altimmune Inc
Antigen Express Inc
Aphios Corp
Aphios Corp
AusBio Ltd
BiondVax Pharmaceuticals Ltd
CaPtivate Pharmaceuticals LLC
CEL-SCI Corp
Chicago Biosolutions Inc
CHO Pharma Inc
Cocrystal Pharma Inc
Curevac AG
Declion Pharmaceuticals Inc
Fides Pharma SPA
Fides Pharma SPA
Forge Life Science LLC
Gamma Vaccines Pty Ltd
General Research Laboratory
Greffex Inc
Hemispherx Biopharma Inc
Karyopharm Therapeutics Inc
Kineta Inc
Lakewood-Amedex Inc
Medicago Inc
Medigen Inc
Medigen Vaccine Biologics Corp
NanoViricides Inc
Ology Bioservices Inc
OPKO Health Inc
PeptiDream Inc
Shionogi & Co Ltd
TGV Laboratories Inc
Tria Bioscience Corp
Vaxine Pty Ltd
Vertex Pharmaceuticals
Virvio Inc

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL INFLUENZA A VIRUS H5N1 SUBTYPE INFECTION PIPELINE MARKET

VI. APPENDIX

1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability